When.com Web Search

  1. Ads

    related to: her2 amplification vs overexpression in breast cancer

Search results

  1. Results From The WOW.Com Content Network
  2. HER2 - Wikipedia

    en.wikipedia.org/wiki/HER2

    HER2 activation results from heterodimerization with another ERBB member or by homodimerization when HER2 concentration are high, for instance in cancer. [8] Amplification or over-expression of this oncogene has been shown to play an important role in the development and progression of certain aggressive types of breast cancer.

  3. Endocrine therapy resistance in breast cancer - Wikipedia

    en.wikipedia.org/wiki/Endocrine_therapy...

    Another receptor that often plays a role in breast cancer, although it is not a hormone receptor, is the human epidermal growth factor receptor 2 (HER2). The overexpression of HER2 is determined by immunohistochemistry (IHC), or with fluorescent in situ hybridization in those equivocal cases where IHC does not provide a clear result.

  4. ErbB - Wikipedia

    en.wikipedia.org/wiki/ErbB

    ErbB2 overexpression can occur in breast, ovarian, bladder, non-small-cell lung carcinoma, as well as several other tumor types. [28] Trastuzumab or Herceptin inhibits downstream signal cascades by selectively binding to the extracellular domain of ErbB-2 receptors to inhibit it. [ 28 ]

  5. Trastuzumab emtansine - Wikipedia

    en.wikipedia.org/wiki/Trastuzumab_emtansine

    Approval was based on KATHERINE (NCT01772472 [25]), a randomized, multicenter, open-label trial of 1486 patients with HER2-positive EBC. [24] Breast tumor samples were required to demonstrate HER2 overexpression defined as 3+ IHC or ISH amplification ratio ≥ 2.0 determined at a central laboratory using Ventana's PATHWAY anti-HER2-/neu (4B5 ...

  6. SKBR3 - Wikipedia

    en.wikipedia.org/wiki/SKBR3

    The HER2 gene product is over-expressed in SkBr3 cells SkBr3 cells were derived from a pleural effusion due to an adenocarcinoma originating in a 43-year-old caucasian female. [ 1 ] The cell line over-expresses the HER2 gene product, which has been implicated in several breast cancer proliferation pathways.

  7. Trastuzumab - Wikipedia

    en.wikipedia.org/wiki/Trastuzumab

    In early-stage HER2-positive breast cancer, trastuzumab-containing regimens improved overall survival (Hazard ratio (HR) = 0.66) and disease-free survival (HR = 0.60). [38] Increased risk of heart failure (RR = 5.11) and decline in left ventricular ejection fraction ( relative risk RR = 1.83) were seen in these trials as well. [ 38 ]

  1. Ads

    related to: her2 amplification vs overexpression in breast cancer